Orelabrutinib for H. pylori-positive gastric MALT lymphoma
Part of Cancer, Digestive system, Infections clinical trials.
This trial tests a targeted drug called orelabrutinib for people with a specific type of stomach lymphoma that is linked to an active H. pylori infection. The goal is to see if the drug can help shrink or control the lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with gastric MALT lymphoma (a slow-growing lymphoma in the stomach lining).
- You have an active H. pylori infection (confirmed by a test like a breath test or stomach tissue sample).
- You are in good enough health to carry out daily activities (ECOG score 0-2).
- Your lymphoma is limited to the stomach and nearby lymph nodes (Lugano stage I or II1).
- You have at least one tumor that can be measured on scans or endoscopy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of low-dose radiation and an oral targeted therapy (orelabrutinib) for patients with a slow-growing type of lymphoma called MALT lymphoma. The goal is to see if this approach can effectively treat the disease while reducing side effects.
This trial tests combining very low-dose radiation therapy with a targeted drug called orelabrutinib (a type of cancer-fighting protein inhibitor) as a first treatment for early-stage MALT lymphoma, a slow-growing blood cancer. The goal is to see if this combination can shrink or control the cancer with fewer side effects than standard chemotherapy.
This trial tests a combination of targeted therapy (orelabrutinib) plus chemotherapy (BR) or antibody therapy (G) for people with untreated marginal zone lymphoma. It aims to see if this combination can help patients who haven't had treatment yet.
This trial tests an oral medication called orelabrutinib as a follow-up treatment after initial therapy for marginal zone lymphoma that hasn't been treated yet. The goal is to see if it helps keep the lymphoma from coming back.
This trial tests a combination of two targeted drugs, orelabrutinib and rituximab, as the first systemic treatment for marginal zone lymphoma. If you have not yet had chemotherapy for your lymphoma and meet certain health criteria, you may be able to join.
This trial tests a combination of targeted therapy (Orelabrutinib) plus standard chemotherapy (Pola-R-CHP) for people with untreated non-GCB diffuse large B-cell lymphoma. The goal is to see if this new mix works better than the usual treatment.
Hear when a new Helicobacter Pylori Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.